NCT05755191View on ClinicalTrials.gov

A Study to Assess NEU-411 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

May 13, 2023

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Healthy
Interventions
DRUG

NEU-411

Oral Doses

DRUG

Placebo

Oral Doses

Trial Locations (1)

Unknown

New Zealand Clinical Research, Christchurch

Sponsors

Lead Sponsor

Neuron23 Inc.
All Listed Sponsors
lead

Neuron23 Inc.

INDUSTRY

NCT05755191 - A Study to Assess NEU-411 in Healthy Participants | Biotech Hunter | Biotech Hunter